Tocagen Presents Updated Tumor Response Data for its Cancer-Selective Gene Therapy Pretty good results. 20% of the patients in the trial responded, but those that responded remain alive at 21-42 months. This means that the median survival they reported, 14.3 months, will go up as time goes on - assuming these patients continue to do well for a while! In the past, I have seen numbers reported of about 8 to 9 months average survival for recurrent gbms.. (this press release doesn't break down the % with anaplastic astrocytoma), but that is with everyone dead at the end of the trial.
And they mention the Musella Foundation as funding part of the work. Your donations at work! :)
We are starting a new fundraiser to raise money specifically to speed up approval for this treatment. For details, go to https://virtualtrials.com/toca_fund.cfm
Pioneering Studies Apply New Immunologic Insights to Glioblastoma This is a completely new way of trying to treat brain tumors by suppressing cells in the blood that travel to the brain tumor and inhibit the immune system.
We (The Musella Foundation) funded part of the project! This is YOUR donations hard at work! Thanks
